Japan · Delayed Price · Currency is JPY Sumitomo Pharma Earnings Call Transcripts
Fiscal Year 2026
-
FY 2025 saw double-digit revenue and profit growth, driven by U.S. sales of ORGOVYX and GEMTESA, while Japan faced headwinds from loss of exclusivity and price revisions. FY 2026 guidance projects further revenue gains, increased R&D, and a focus on new product launches and financial stability.
-
Q3 FY2025 saw strong revenue and profit growth, driven by North American product sales and cost controls. Full-year guidance is unchanged due to expected Q4 seasonality, while oncology R&D and partnering timelines have shifted to maximize asset value.
-
Q2 FY2025 saw revenue and profit surge above forecasts, driven by strong North America sales, a JPY 49 billion gain from the China-Asia business transfer, and disciplined cost control. Full-year guidance was raised, with Orgovyx expected to surpass $1 billion in sales.
-
Q1 FY2025 saw strong revenue and profit growth, led by North America, with ORGOVYX and GEMTESA outperforming plans. Full-year guidance is unchanged due to uncertainties, but significant one-time gains are expected in H1. R&D and governance initiatives continue to advance.
Fiscal Year 2025
-
Revenue and profit rebounded sharply in FY 2024, driven by U.S. sales of key products and major cost reductions. FY 2025 guidance anticipates lower revenue due to business transfers and FX, but higher core operating profit, with continued focus on R&D and debt reduction.
-
Returned to profitability with strong revenue growth and cost reductions, raising full-year forecasts. North American products outperformed, while Japan faced headwinds from loss of exclusivity. Ongoing refinancing and R&D prioritization continue.